



Remicade and biosimilars

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720.** If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date:** _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: Same as Requesting Provider

Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: Same as Referring Provider Same as Requesting Provider

Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____ kg

Patient Height: _____ cm

Site of Service Questions:

- A. Where will this drug be administered?
- | | |
|---|---|
| <input type="checkbox"/> Ambulatory surgical, <i>skip to Clinical Questions</i> | <input type="checkbox"/> Home infusion, <i>skip to Clinical Questions</i> |
| <input type="checkbox"/> Off-campus Outpatient Hospital | <input type="checkbox"/> On-campus Outpatient Hospital |
| <input type="checkbox"/> Physician office, <i>skip to Clinical Questions</i> | <input type="checkbox"/> Pharmacy, <i>skip to Clinical Questions</i> |
- B. Is this request to continue previously established treatment with the requested medication?
- Yes – This is a continuation of an existing treatment
- Yes – This is a continuation request, however a gap in therapy of greater than 2 doses has occurred. *Skip to Clinical Criteria Questions*
- No – This is a new therapy request (patient has not received requested medication in the last 6 months). *Skip to Clinical Criteria Questions*
- No – This is a request for a different brand infliximab product that the patient has not received previously. *Skip to Clinical Criteria Questions*
- C. Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (eg acetaminophen, steroids, diphenhydramine, fluids, other pre- medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Remicade and biosimilars SOC SGM 2182-A – 07/2022.

CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062

Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com

seizures) during or immediately after an infusion? **ACTION REQUIRED: If Yes, please attach supporting clinical documentation.** Yes, skip to Clinical Criteria Questions No

- D. Does the patient have laboratory confirmed antibodies to infliximab? **ACTION REQUIRED: If Yes, please attach supporting clinical documentation.** Yes, skip to Clinical Criteria Questions No
- E. Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment?
ACTION REQUIRED: If Yes, please attach supporting clinical documentation.
 Yes, skip to Clinical Criteria Questions No
- F. Does the patient have severe venous access issues that require the use of a special interventions only available in the outpatient hospital setting? **ACTION REQUIRED: If Yes, please attach supporting clinical documentation.**
 Yes, skip to Clinical Criteria Questions No
- G. Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver?
ACTION REQUIRED: If Yes, please attach supporting clinical documentation. Yes No

Criteria Questions:

1. What is the prescribed drug? Remicade Avsola Inflectra Renflexis
2. What is the prescribed dose and frequency?
 - a) **Loading dose:**
 Remicade 100 mg Quantity and Frequency: _____
 Avsola 100 mg Quantity and Frequency: _____
 Inflectra 100 mg Quantity and Frequency: _____
 Renflexis 100 mg Quantity and Frequency: _____
 Other _____
 - b) **Maintenance dose:**
 Remicade 100 mg Quantity and Frequency: _____
 Avsola 100 mg Quantity and Frequency: _____
 Inflectra 100 mg Quantity and Frequency: _____
 Renflexis 100 mg Quantity and Frequency: _____
 Other _____
 - c) **Dosing (other):** *Indicate all that apply.*
 This is a request for a change in dosing regimen.
 The requested quantity is supported by dosing guidelines found in the compendia or current literature (e.g., Micromedex DrugDex, NCCN compendia, current treatment guidelines).
 The patient requires a dose above 5 mg per kg due to loss of response at current dose.
 The patient requires a dose above 3 mg per kg due to an incomplete response at current dose.
3. Has the patient been diagnosed with any of the following? *List continues on next page.*
 Moderately to severely active Crohn's disease (CD)
 Moderately to severely active ulcerative colitis (UC)
 Moderately to severely active rheumatoid arthritis (RA)
 Active ankylosing spondylitis (AS)
 Active axial spondyloarthritis
 Active psoriatic arthritis WITHOUT co-existent plaque psoriasis (PsA)
 Active psoriatic arthritis with co-existent plaque psoriasis (PsA)
 Moderate to severe plaque psoriasis
 Juvenile idiopathic arthritis

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Remicade and biosimilars SOC SGM 2182-A – 07/2022.

CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062

Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com

- Behcet's disease
 - Granulomatosis with polyangiitis (Wegener's granulomatosis)
 - Severe, refractory hidradenitis suppurativa
 - Pyoderma gangrenosum
 - Sarcoidosis
 - Refractory Takayasu's arteritis
 - Uveitis
 - Reactive arthritis
 - Immune checkpoint inhibitor (e.g., CTLA-4, PD-L1 inhibitor) toxicity
 - Acute graft versus host disease
 - Other _____
4. What is the ICD-10 code? _____
5. What is the patient's weight? ___kg or lbs (*circle one*)
6. Is the patient currently receiving Remicade or a biosimilar? Yes No

Section A: All Requests

7. Will the requested drug be used in combination with any other biologic (e.g., Humira) or targeted synthetic disease-modifying anti-rheumatic drug (DMARD) (e.g., Olumiant, Otezla, Xeljanz)?
 Yes No
8. Has the patient ever received (including current utilizers) a biologic (e.g., Humira) or targeted synthetic DMARD (e.g., Olumiant, Xeljanz) associated with an increased risk of tuberculosis (TB)?
If Yes, skip to #12 Yes No
9. Has the patient had a tuberculosis (TB) test (e.g., tuberculosis skin test [PPD], interferon-release assay [IGRA], chest x-ray) within 6 months of initiating therapy? Yes No
10. What were the results of the tuberculosis (TB) test?
 Positive for TB Negative for TB, *skip to #12* Unknown
11. Which of the following applies to the patient?
 Patient has latent TB and treatment for latent TB has been initiated
 Patient has latent TB and treatment for latent TB has been completed
 Patient has latent TB and treatment for latent TB has not been initiated
 Patient has active TB
12. Is this request for continuation of therapy with the requested drug or a biosimilar?
 Yes No *If No, skip to #15*
13. Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program? *If Yes or Unknown, skip to #15* Yes No Unknown
14. Has the patient achieved or maintained positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition since starting treatment with the requested drug?
 Yes No
15. Has the patient ever received (including current utilizers) any of the following? ***ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried.***
 A biologic (e.g., Humira, Cimzia, Enbrel) indicated for the diagnosis, *indicate biologic:* _____
 Targeted synthetic disease modifying drug (e.g., Rinvoq, Xeljanz) indicated for the diagnosis
 Otezla
 No - None of the above

Complete the following section based on the patient's diagnosis, if applicable.

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Remicade and biosimilars SOC SGM 2182-A – 07/2022.

CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062

Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com

Section B: Crohn's Disease

16. Has the patient achieved or maintained remission? **ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation of remission and no further questions.** Yes No
17. *If the patient is less than 18 years old*, does the prescriber recognize that a dose above 5 mg per kg is a higher dose and the prescriber confirms that appropriate monitoring will be done? Yes No

Continuation

18. Which of the following has the patient experienced an improvement in from baseline? **ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response to therapy and no further questions.**
- Abdominal pain or tenderness
 - Diarrhea
 - Body weight
 - Abdominal mass
 - Hematocrit
 - Endoscopic appearance of the mucosa
 - Improvement on a disease activity scoring tool (e.g., Crohn's Disease Activity Index [CDAI] score)
 - None of the above

Initiation

19. Is the patient less than 18 years of age? *If Yes, no further questions* Yes No
20. Does the patient have fistulizing disease? **ACTION REQUIRED: If Yes, please attach chart notes or medical record documentation supporting diagnosis. and no further questions.** Yes No
21. Has the patient tried and had an inadequate response to at least one conventional therapy option? **ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and no further questions.**
- Yes - Sulfasalazine (Azulfidine, Sulfazine) Yes - Budesonide (Entocort EC)
 - Yes - Mercaptopurine (Purinethol) Yes - Azathioprine (Azasan, Imuran)
 - Yes - Metronidazole (Flagyl) Yes - Methotrexate IM or SC
 - Yes - Ciprofloxacin (Cipro) Yes - Methylprednisolone (Solu-Medrol)
 - Yes - Prednisone Yes - Rifaximin (Xifaxan)
 - Yes - Tacrolimus No
22. Does the patient have a contraindication or intolerance to at least one conventional therapy option (e.g., azathioprine [Azasan, Imuran], budesonide [Entocort EC], ciprofloxacin [Cipro], mercaptopurine [Purinethol], methylprednisolone [Solu-Medrol], methotrexate IM or SC, metronidazole [Flagyl], prednisone, sulfasalazine [Azulfidine, Sulfazine], rifaximin [Xifaxan], tacrolimus)? **ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy. If therapy is not advisable, please attach documentation of clinical reason to avoid therapy.** Yes No

Section C: Ulcerative Colitis

23. What is the patient's age?
- Less than 18 years old *Skip to #25*
 - 18 years of age or older
24. Was the patient on a dose exceeding 5 mg per kg as a pediatric patient and is continuing that dose into adulthood? Yes No
25. Does the prescriber recognize that a dose above 5 mg per kg is a higher dose and the prescriber confirms that appropriate monitoring will be done? Yes No

Continuation

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Remicade and biosimilars SOC SGM 2182-A – 07/2022.

CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062

Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com

26. Has the patient achieved or maintained remission? ***ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation of remission and no further questions.*** Yes No
27. Which of the following has the patient experienced an improvement in from baseline? ***ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response to therapy and no further questions.***
- Stool frequency
 - Rectal bleeding
 - Urgency of defecation
 - C-reactive protein (CRP)
 - Fecal calprotectin (FC)
 - Endoscopic appearance of the mucosa
 - Improvement on a disease activity scoring tool (e.g., Ulcerative Colitis Endoscopic Index of Severity [UCEIS], Mayo Score)
 - None of the above

Initiation

28. Has the patient been hospitalized for fulminant ulcerative colitis (e.g., continuous bleeding, severe toxic symptoms, including fever and anorexia)? ***ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation of hospitalization and no further questions.*** Yes No
29. Has the patient tried and had an inadequate response to at least one conventional therapy option? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and no further questions.***
- Yes - Azathioprine (Azasan, Imuran)
 - Yes - Corticosteroid (e.g., hydrocortisone [Cortifoam, Colocort, Solu-Cortef, Cortef], methylprednisolone [Medrol, Solu-Medrol], prednisone)
 - Yes - Cyclosporine (Sandimmune)
 - Yes - Mesalamine (e.g., Apriso, Asacol, Lialda, Pentasa, Canasa, Rowasa), balsalazide, or olsalazine
 - Yes - Mercaptopurine (Purinethol)
 - Yes - Sulfasalazine
 - Yes - Tacrolimus (Prograf)
 - No
30. Does the patient have a contraindication or intolerance to at least one conventional therapy option (e.g., azathioprine [Azasan, Imuran], corticosteroid [e.g., hydrocortisone, methylprednisolone, prednisone], cyclosporine [Sandimmune], mesalamine [Asacol, Lialda, Pentasa, Canasa, Rowasa], balsalazide, olsalazine, mercaptopurine [Purinethol], sulfasalazine, tacrolimus [Prograf])? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried. If therapy is not advisable, please attach documentation of clinical reason to avoid therapy.*** Yes No

Section D: Rheumatoid Arthritis and Reactive Arthritis

Continuation

31. *If the diagnosis is rheumatoid arthritis*, has the patient achieved or maintained positive clinical response since starting treatment with the requested drug? Yes No
32. *If diagnosis is reactive arthritis*, has the patient achieved or maintained positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition (e.g., tender joint count, swollen joint count, or pain)? ***ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation supporting positive clinical response and no further questions.*** Yes No
33. What is the percent of disease activity improvement from baseline in tender joint count, swollen joint count, pain, or disability? ***ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response.*** _____%.
No further questions.

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Remicade and biosimilars SOC SGM 2182-A – 07/2022.

CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062

Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com

Initiation – for diagnosis of Reactive Arthritis, skip to #37

34. Is the requested medication being prescribed in combination with methotrexate or leflunomide?
 Yes No *If No, indicate clinical reason for not using methotrexate or leflunomide:*

35. Does the patient meet either of the following: a) the patient was tested for the rheumatoid factor (RF) biomarker and the RF biomarker test was positive, or b) the patient was tested for the anti-cyclic citrullinated peptide (anti-CCP) biomarker and the anti-CCP biomarker test was positive? ***ACTION REQUIRED: If ‘Yes’, please attach laboratory results, chart notes, or medical record documentation of biomarker testing and skip to #37.*** Yes No
36. Has the patient been tested for all of the following biomarkers: a) rheumatoid factor (RF), b) anti-cyclic citrullinated peptide (anti-CCP), and c) C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR)? ***ACTION REQUIRED: If ‘Yes’, please attach laboratory results, chart notes, or medical record documentation of biomarker testing.*** Yes No
37. Has the patient experienced an inadequate response after at least 3 months of treatment with methotrexate at a dose greater than or equal to 15 mg per week? ***ACTION REQUIRED: If ‘Yes’, please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy. Indicate below and no further questions.*** Yes No
38. Has the patient experienced an intolerance to methotrexate? ***ACTION REQUIRED: If ‘Yes’, please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy. Indicate below and no further questions.*** Yes No
39. Does the patient have a contraindication to methotrexate? ***ACTION REQUIRED: If ‘Yes’, please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including clinical reason to avoid therapy.*** Yes No
If Yes, indicate the contraindication: _____

Section E: Ankylosing Spondylitis or Active Axial Spondyloarthritis

Continuation

40. Which of the following has the patient experienced an improvement in from baseline? ***ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response to therapy and no further questions.***
- | | |
|--|---|
| <input type="checkbox"/> Functional status | <input type="checkbox"/> Inflammation (e.g., morning stiffness) |
| <input type="checkbox"/> Total spinal pain | <input type="checkbox"/> None of the above |

Initiation

41. Has the patient experienced an inadequate response with at least TWO nonsteroidal anti-inflammatory drugs (NSAIDs), or has an intolerance or contraindication to at least two NSAIDs? ***ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy. If therapy is not advisable, please attach documentation of clinical reason to avoid therapy.*** Yes No

Section F: Psoriatic Arthritis

Continuation

42. Which of the following has the patient experienced an improvement in from baseline? ***ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response.***
- | |
|---|
| <input type="checkbox"/> Number of swollen joints |
| <input type="checkbox"/> Number of tender joints |
| <input type="checkbox"/> Dactylitis |
| <input type="checkbox"/> Enthesitis |
| <input type="checkbox"/> Skin and/or nail involvement |
| <input type="checkbox"/> None of the above |

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Remicade and biosimilars SOC SGM 2182-A – 07/2022.

CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062

Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com

Section G: Plaque Psoriasis

Continuation

43. Has the patient experienced a reduction in body surface area (BSA) affected from baseline?
ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation of decreased body surface area affected. Yes No
44. Has the patient experienced an improvement in signs and symptoms of the condition from baseline (e.g., itching, redness, flaking, scaling, burning, cracking, pain)? **ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation of improvement in signs and symptoms.** Yes No

Initiation

45. Are crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) affected?
ACTION REQUIRED: If 'Yes', please attach chart notes or medical record documentation of affected areas and body surface area affected. Yes No
46. What is the percentage of body surface area (BSA) affected (prior to starting the requested medication)? **ACTION REQUIRED: Please attach chart notes or medical record documentation of affected areas and body surface area affected.** _____% *If greater than or equal to 10% of BSA, no further questions.*
47. Has the patient experienced an inadequate response, or has an intolerance to phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine or acitretin? **ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy.** Yes No
48. Does the patient have a clinical reason to avoid pharmacologic treatment with methotrexate, cyclosporine and acitretin? **ACTION REQUIRED: If 'Yes', please attach documentation of clinical reason to avoid therapy.** Yes No
If Yes, indicate the clinical reason: _____

Section H: Juvenile Idiopathic Arthritis

Continuation

49. Which of the following has the patient experienced an improvement in from baseline? **ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response.**
- Number of joints with active arthritis (e.g., swelling, pain, limitation of motion)
 - Number of joints with limitation of movement
 - Functional ability
 - None of the above

Initiation

50. Has the patient experienced an inadequate response to ANY of the following? **ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy. Indicate below and no further questions.**
- At least 1 month trial of NSAIDs
 - At least 2 weeks of treatment with corticosteroids (e.g. prednisone, methylprednisolone)
 - At least 3 months of treatment with methotrexate
 - At least 3 months of treatment with leflunomide
 - No – No history of an inadequate response to any of the above

Section I: Behcet's Disease

51. Has the patient had an inadequate response to at least one nonbiologic medication for Behcet's disease (e.g., apremilast, colchicine, systemic glucocorticoids, azathioprine)? **ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy** Yes No

Section J: Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Pyoderma Gangrenosum, Sarcoidosis. and

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Remicade and biosimilars SOC SGM 2182-A – 07/2022.

CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062

Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com

Takayasu's Arteritis

52. Has the patient experienced ANY of the following with corticosteroids or immunosuppressive therapy (e.g., cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil)?

ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and documentation of clinical reason to avoid therapy. Indicate ALL that apply.

- Corticosteroids Inadequate response Intolerance Contraindication
 Immunosuppressive therapy Inadequate response Intolerance Contraindication

If immunosuppressive therapy, specify therapy: _____

- None of the above

Section K: Hidradenitis Suppurativa

Continuation

53. Which of the following has the patient experienced since starting treatment with the requested drug? **ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response.**

- Reduction in abscess and inflammatory nodule count from baseline
 Reduced formation of new sinus tracts and scarring
 Decrease in frequency of inflammatory lesions from baseline
 Reduction in pain from baseline
 Reduction in suppuration from baseline
 Improvement in frequency of relapses from baseline
 Improvement in quality of life from baseline
 Improvement on a disease severity assessment tool from baseline
 None of the above

Initiation

54. Has the patient experienced an inadequate response after at least 90 days of treatment with oral antibiotics?

ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and no further questions.

- Yes No

55. Has the patient experienced an intolerable adverse effect to oral antibiotics? **ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and no further questions.** Yes No

56. Does the patient have a contraindication to oral antibiotics? **ACTION REQUIRED: If 'Yes', please attach documentation of clinical reason to avoid therapy.** Yes No

Section L: Uveitis

Continuation

57. Which of the following has the patient experienced since starting treatment with the requested drug? **ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response.**

- Reduced frequency of recurrence compared to baseline
 Zero anterior chamber inflammation or reduction in anterior chamber inflammation compared to baseline
 Decreased reliance on topical corticosteroids
 None of the above

Initiation

58. Has the patient experienced ANY of the following with corticosteroids or immunosuppressive therapy (e.g., cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil)? **Indicate ALL that apply.**

ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy, or clinical reason to avoid therapy.

- Corticosteroid Inadequate response Intolerance Contraindication
 Immunosuppressive therapy Inadequate response Intolerance Contraindication

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Remicade and biosimilars SOC SGM 2182-A – 07/2022.

CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062

Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com

If immunosuppressive therapy, specify therapy: _____

None of the above

Section M: Immune Checkpoint Inhibitor Toxicity

59. Has the patient experienced an inadequate response to corticosteroids? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and no further questions.*** Yes No
60. Has the patient experienced an intolerance to corticosteroids? ***ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and no further questions.*** Yes No
61. Does the patient have a contraindication to corticosteroids? ***ACTION REQUIRED: If 'Yes', please attach documentation of clinical reason to avoid therapy and no further questions.*** Yes No
62. Does the patient have cardiac toxicity? *If Yes, no further questions* Yes No
63. Does the patient have moderate or severe diarrhea or colitis? Yes No

Section N: Acute Graft Versus Host Disease

64. Has the patient experienced an inadequate response to systemic corticosteroids? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and no further questions.*** Yes No
65. Does the patient have an intolerance or contraindication to corticosteroids? ***ACTION REQUIRED: If 'Yes', please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy. If therapy is not advisable, please attach documentation of clinical reason to avoid therapy.*** Yes No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X _____

Prescriber or Authorized Signature

Date (mm/dd/yy)

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Remicade and biosimilars SOC SGM 2182-A – 07/2022.

CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062

Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com